Broccoli for Cancer Chemoprevention

Broccoli is the single most-studied dietary chemopreventive agent in modern oncology research. Paul Talalay's 1992 PNAS paper identifying sulforaphane as the major broccoli-derived inducer of cancer-protective phase II enzymes launched a 30-year research program that has now produced cohort epidemiology, animal models in nearly every solid-tumor type, and several modest but positive human RCTs. The mechanism is multimodal: accelerated phase II conjugation of carcinogens (the original Nrf2-mediated story); direct histone deacetylase inhibition that re-activates tumor suppressor gene expression; cell cycle arrest at G2/M and pro-apoptotic effects on transformed cells; angiogenesis suppression; and modulation of cancer stem cell self-renewal. The Cipolla 2015 prostate cancer trial in biochemical-recurrence patients and the Cantwell osteosarcoma series provide the human bridge between mechanism and clinical effect. Realistic framing matters: broccoli is best understood as a prevention strategy and an adjunct, not as a primary treatment for established cancer.

Table of Contents

  1. Talalay's 1992 Discovery
  2. The Qidong Aflatoxin Chemoprevention Trials
  3. HDAC Inhibition as a Second Mechanism
  4. Breast Cancer Evidence
  5. Prostate Cancer Evidence (Cipolla RCT)
  6. Bladder and Urothelial Cancer
  7. Colorectal Cancer
  8. Lung Cancer Chemoprevention
  9. Effects on Cancer Stem Cells
  10. What Broccoli Does Not Do
  11. Key Research Papers
  12. Connections

Talalay's 1992 Discovery

The modern broccoli chemoprevention story begins in 1992 at the Johns Hopkins School of Medicine, where Paul Talalay and his postdoctoral fellow Yuesheng Zhang had spent years searching for the molecular agent responsible for the observed protective effect of cruciferous vegetables in carcinogen-induced rodent tumor models. The lab's screening approach was operationally elegant: extract a vegetable, fractionate the extract by chromatography, and assay each fraction for its ability to induce the phase II marker enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) in murine hepatoma cells in culture.

Broccoli extracts repeatedly produced the highest NQO1 induction of any tested vegetable. The active fraction was isolated, crystallized, and structurally characterized as sulforaphane — the isothiocyanate derived from the glucosinolate glucoraphanin. The 1992 PNAS paper (Zhang Y, Talalay P, Cho CG, Posner GH) reporting the isolation, structure, and chemopreventive activity of sulforaphane is one of the most highly cited papers in food chemoprevention research, with over 2,000 citations.

The Talalay laboratory subsequently demonstrated that sulforaphane prevented mammary tumor formation in DMBA (7,12-dimethylbenz[a]anthracene)-treated rats by approximately 50%, providing the first mammalian whole-animal in vivo demonstration that the dietary molecule could prevent chemically-induced cancer. The follow-up 1997 paper (Fahey JW, Zhang Y, Talalay P, PNAS) demonstrated that 3-day-old broccoli sprouts contained 20-50 times the glucoraphanin per gram of mature broccoli — redirecting much of the subsequent research toward sprouts as a more concentrated source.

Back to Table of Contents

The Qidong Aflatoxin Chemoprevention Trials

The most rigorous human chemoprevention evidence for broccoli comes from a series of trials conducted in Qidong, Jiangsu province, China — a region historically characterized by both very high aflatoxin contamination of dietary staples (corn and peanuts) and one of the highest age-adjusted hepatocellular carcinoma incidence rates in the world. The Qidong studies were led by Thomas Kensler at Johns Hopkins in collaboration with Chinese investigators (Patricia Egner, John Groopman, Lisheng Liu, and others) over more than two decades.

The first major trial in this series (Kensler et al. 2005, Cancer Epidemiology Biomarkers & Prevention, JID 15827087) randomized 200 healthy adults to either a broccoli sprout hot-water infusion (containing approximately 400 micromol glucoraphanin daily) or a placebo for two weeks. Urinary aflatoxin-DNA adducts and aflatoxin-mercapturic acid metabolites were measured at multiple timepoints. The intervention significantly accelerated aflatoxin elimination via increased glutathione conjugation, with the magnitude of effect correlating with individual glutathione S-transferase M1 (GSTM1) genotype — GSTM1-null subjects had blunted but still measurable responses.

Subsequent Qidong trials extended the work to air pollutants, particularly benzene and acrolein from the heavy industrial air pollution of the region. The Egner 2014 trial (Cancer Prevention Research, JID 24913818) randomized 291 subjects to a 12-week broccoli sprout beverage intervention and demonstrated a 61% increase in urinary benzene-mercapturate and 23% increase in acrolein-mercapturate excretion, sustained throughout the intervention.

These Qidong trials are widely considered the strongest human-subject evidence that a dietary intervention can measurably accelerate carcinogen elimination at clinically meaningful magnitudes. They do not prove cancer prevention in humans — that would require a multi-decade outcome trial that has not been done — but they bridge mechanism to a verifiable biochemical effect in real people.

Back to Table of Contents

HDAC Inhibition as a Second Mechanism

Beyond the Nrf2/phase II enzyme story that dominated the first decade of sulforaphane research, the Roderick Dashwood laboratory at Oregon State University (subsequently at Texas A&M) demonstrated a second, mechanistically distinct anti-cancer activity: histone deacetylase (HDAC) inhibition. This is an epigenetic mechanism that re-activates silenced tumor suppressor genes by preventing histone deacetylation around their promoters, leaving the chromatin in a permissively transcribed state.

The Myzak 2007 paper (Experimental Biology and Medicine, JID 17202570) showed that sulforaphane administered orally to humans (a single 68 g serving of broccoli sprouts) inhibited HDAC activity in peripheral blood mononuclear cells, demonstrating that the mechanism is achievable at dietary doses. The active species responsible for HDAC inhibition is not sulforaphane itself but its glutathione conjugate metabolite (sulforaphane-glutathione) and downstream cysteine conjugate, both of which are formed during phase II metabolism.

The clinical importance of HDAC inhibition is well-established in oncology: several FDA-approved cancer drugs (vorinostat for cutaneous T-cell lymphoma, romidepsin, panobinostat) work primarily as HDAC inhibitors. Their molecular effect is the same one that sulforaphane achieves at dietary doses — re-activation of p21 (the cell cycle inhibitor), Bax (pro-apoptotic), and other silenced tumor suppressors in transformed cells. The dietary HDAC inhibition is naturally much milder than the pharmaceutical agents, but it is present, mechanistically real, and contributes to the overall chemopreventive effect.

Back to Table of Contents

Breast Cancer Evidence

Breast cancer was the first solid tumor in which sulforaphane chemoprevention was demonstrated in vivo (Zhang Y et al. 1994, PNAS: DMBA-induced mammary tumor prevention in rats). The mechanism is multimodal: phase II conjugation of estrogen metabolites that act as DNA-damaging electrophiles (particularly the 4-hydroxyestrogen quinone-imines); HDAC inhibition reactivating tumor suppressor genes commonly silenced in breast cancer; and direct effects on cancer stem cells (next section).

The Atwell 2015 trial (Cancer Prevention Research, JID 26100133) measured sulforaphane uptake and biomarker effects in breast tissue obtained at biopsy from women scheduled for evaluation of suspicious lesions. After a short-term broccoli sprout intervention, sulforaphane and its metabolites were detectable in breast tissue, and the expected molecular pharmacodynamic effects (mild reduction in Ki-67 proliferation index, induction of HDAC inhibition markers) were demonstrable, although the magnitude was modest and the trial was not powered for clinical endpoints.

Population-level epidemiology is supportive but not definitive. The pooled analysis of the Nurses' Health Study cohorts found inverse associations between cruciferous vegetable intake and premenopausal breast cancer risk; the magnitude is modest (approximately 15% relative risk reduction at the highest quintile of intake). Mediterranean and East Asian dietary pattern studies also support an inverse relationship, although confounding by other healthy-diet behaviors makes single-food attribution difficult.

Back to Table of Contents

Prostate Cancer Evidence (Cipolla RCT)

Prostate cancer has produced one of the most informative human RCTs in the sulforaphane chemoprevention literature: the Cipolla 2015 trial (Cancer Prevention Research, JID 25712054), a randomized double-blind placebo-controlled study in 78 men with biochemical recurrence of prostate cancer after radical prostatectomy. Subjects received either daily oral sulforaphane (60 mg/day standardized broccoli sprout extract) or placebo for 6 months.

The primary endpoint was the change in prostate-specific antigen (PSA) doubling time, a validated surrogate for the rate of biochemical recurrence and a clinically meaningful endpoint in the active-surveillance population. The trial demonstrated:

This trial is the strongest human evidence to date that broccoli-derived sulforaphane produces a clinical (not just biochemical or biomarker) effect on prostate cancer biology. The effect size is real but modest, consistent with broccoli's role as an adjunct rather than a primary therapy. The Cipolla trial also provides a model for how dietary chemoprevention research should be conducted: in patients with measurable disease and surrogate endpoints that respond on a months-to-year timescale.

Mechanism for prostate cancer specifically includes: Nrf2-driven phase II conjugation of androgen-related electrophilic metabolites; HDAC inhibition reactivating prostate-cancer-specific silenced tumor suppressors; direct cytotoxicity to prostate cancer stem cells (the Myzak PC-3 xenograft work); and modulation of the androgen receptor signaling axis at sustained micromolar concentrations.

Back to Table of Contents

Bladder and Urothelial Cancer

Bladder cancer is one of the few solid tumors where the epidemiologic case for cruciferous vegetable consumption is particularly strong, owing to the unique pharmacology of urinary excretion. Isothiocyanate metabolites (the N-acetylcysteine conjugates, also known as mercapturic acids) are concentrated in urine during renal excretion, achieving local concentrations in the bladder lumen substantially higher than in any other tissue. This delivers sustained sulforaphane-equivalent exposure to the urothelium for hours after ingestion.

The Tang 2008 case-control study (Cancer Epidemiology Biomarkers and Prevention, JID 18268127) reported a 36% reduction in bladder cancer risk among the highest quartile of raw cruciferous vegetable consumers, with raw consumption showing stronger associations than cooked — consistent with the bioavailability difference between intact-myrosinase raw cruciferous and overcooked vegetables where myrosinase is destroyed. The follow-up Bhattacharya 2010 paper demonstrated allyl isothiocyanate (a related compound from mustard seed and horseradish) prevented bladder cancer development in an experimental rodent model.

The mechanistic and epidemiologic case combined makes a reasonable argument for broccoli (and especially broccoli sprouts) as a chemopreventive food for patients at elevated bladder cancer risk — current and former smokers, occupational exposure to aromatic amines, and individuals with prior non-muscle-invasive bladder cancer at risk for recurrence. Clinical trials in BCG-non-responsive non-muscle-invasive bladder cancer are under way.

Back to Table of Contents

Colorectal Cancer

Colorectal cancer evidence for sulforaphane has progressed slowly because the gut lumen presents a particular bioavailability challenge: the intact mature broccoli's glucoraphanin can pass through the small intestine and reach the colon, where its hydrolysis depends on the gut microbiome's bacterial myrosinase activity, which varies substantially across individuals. Subjects with low bacterial myrosinase activity get less colonic sulforaphane exposure than those with high activity, blunting the chemopreventive effect.

Despite this, mechanistic studies in colon cancer cell lines and animal models consistently show favorable effects: Nrf2-driven detoxification, HDAC inhibition with reactivation of p21 and other tumor suppressors, induction of apoptosis in transformed colonocytes (with relative sparing of normal colonocytes), and suppression of NF-kB-driven inflammatory signaling that drives the colitis-cancer sequence in inflammatory bowel disease.

Epidemiologic data are supportive but inconsistent. Some pooled cohort analyses show modest inverse associations between cruciferous vegetable intake and colorectal cancer risk; others are null. The GSTM1 genotype interaction is replicated: subjects with the GSTM1-null genotype, who would be predicted to have reduced glutathione conjugation efficiency, paradoxically benefit more from cruciferous vegetable intake — possibly because the unconjugated isothiocyanate has a longer residence time and more opportunity to engage Keap1 in the colonocyte.

For inflammatory bowel disease patients at elevated colorectal cancer risk from chronic mucosal inflammation, broccoli sprouts have been evaluated in small pilot studies with favorable safety and biomarker results. See Inflammatory Bowel Disease.

Back to Table of Contents

Lung Cancer Chemoprevention

Lung cancer is the leading cause of cancer death worldwide and the obvious target for any chemopreventive food given the well-defined population of high-risk smokers. The relevant mechanisms for broccoli/sulforaphane in lung cancer include the same Nrf2-driven phase II conjugation that accelerated benzene mercapturate excretion in the Qidong trials, plus direct effects on the airway epithelium where many lung cancers originate.

The Hecht laboratory at the University of Minnesota has produced the most thorough mechanistic work, demonstrating that isothiocyanates (sulforaphane plus the related PEITC from watercress) prevent NNK (nicotine-derived nitrosamine ketone, the major tobacco carcinogen) induced lung tumors in rodent models by inducing phase II conjugation of NNK's reactive intermediates and by directly inhibiting cytochrome P450 2A6, the enzyme that activates NNK to its carcinogenic form.

Human chemoprevention trials in lung cancer have been less clear-cut. The largest trial of cruciferous-derived isothiocyanates for lung cancer prevention — the Hecht-led PEITC trial in smokers — demonstrated reduced urinary excretion of NNK metabolites consistent with reduced internal dose, but the trial was not large enough or long enough to assess cancer outcomes. Practically: for current smokers, smoking cessation is by far the most important intervention; for former smokers and those with continued environmental exposure to combustion pollutants, cruciferous vegetable consumption is a modest but reasonable adjunctive measure.

Back to Table of Contents

Effects on Cancer Stem Cells

Perhaps the most interesting and most recent direction in sulforaphane oncology research concerns its effect on cancer stem cells — the rare self-renewing subpopulation within solid tumors that drives long-term tumor growth and metastatic recurrence after conventional treatment. Cancer stem cells are typically more resistant to chemotherapy and radiation than the bulk tumor population, which is one of the reasons that "complete response" by imaging often precedes eventual recurrence.

Several laboratories have demonstrated that sulforaphane preferentially depletes cancer stem cell populations in vitro, including breast cancer stem cells (the CD44+/CD24- subpopulation), pancreatic cancer stem cells (the ALDH+ subpopulation), and prostate cancer stem cells. The mechanism appears to involve disruption of cancer stem cell self-renewal signaling pathways (NF-kB, Sonic hedgehog, Wnt/beta-catenin) and induction of differentiation in the stem cell subpopulation.

Clinical translation is in early stages. The most provocative human data come from pancreatic cancer, where the Hagen-Pohlmann group in Germany has conducted a series of small pilot trials of standardized broccoli sprout extract as an adjunct to conventional chemotherapy in advanced pancreatic cancer patients, with suggestion of improved tolerability and (in retrospective analyses) modest survival benefits. These remain preliminary observations rather than definitive evidence.

Back to Table of Contents

What Broccoli Does Not Do

Honest framing of the chemoprevention evidence requires noting several things broccoli does not do, despite occasional overstated marketing claims:

The realistic framing: broccoli (especially sprouts) is one of the most evidence-supported dietary interventions for primary cancer prevention, with documented mechanism, replicated human biomarker effects, and modest positive clinical trials. It is a strong addition to a primary prevention strategy, a reasonable adjunct in active surveillance and biochemical-recurrence populations, and a modest complementary supportive measure during active cancer treatment. It is not a cancer cure.

Back to Table of Contents

Key Research Papers

  1. Zhang Y, Talalay P, Cho CG, Posner GH (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. PNAS. — PubMed
  2. Fahey JW, Zhang Y, Talalay P (1997). Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. PNAS. — PubMed
  3. Cipolla BG et al. (2015). Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev Res. — PubMed
  4. Kensler TW et al. (2005). Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts in Qidong, China. Cancer Epidemiol Biomarkers Prev. — PubMed
  5. Egner PA et al. (2014). Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China. Cancer Prev Res. — PubMed
  6. Myzak MC et al. (2007). Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med. — PubMed
  7. Tang L et al. (2008). Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev. — PubMed
  8. Atwell LL et al. (2015). Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy. Cancer Prev Res. — PubMed
  9. Higdon JV et al. (2007). Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. — PubMed
  10. Verhoeven DT et al. (1996). Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev. — PubMed
  11. Hecht SS (2000). Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev. — PubMed
  12. Joseph MA et al. (2004). Cruciferous vegetables, genetic polymorphisms in GSTM1 and GSTT1, and prostate cancer risk. Nutr Cancer. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents